Alcon Pharmaceuticals Overview
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. Alcon Pharmaceuticals office in Israel was established following the acquisition of Belkin Vision.
Latest News
growth-positive
CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls
The article highlights recent research calls on Wall Street, focusing on upgrades and downgrades of various companies. HP Enterprise (HPE) was upgraded by Morgan Stanley to Overweight with a price target increase, indicating a positive outlook due to potential benefits from the Juniper acquisition. CoreWeave and Bio-Techne also received upgrades with increased price targets, suggesting undervaluation and growth potential. Conversely, companies like Instacart and Coty faced downgrades due to increased competition and weaker-than-expected results. The article provides insights into market perceptions and expectations for these companies.
growth-positive
Alcon acquiring glaucoma laser therapy developer Belkin Vision for up to $330 million | CTech
Alcon Pharmaceuticals is acquiring Israeli healthtech company Belkin Vision, according to a report filed by BioLight to the Tel Aviv Stock Exchange. Belkin Vision, valued at up to $330 million, has developed a non-contact automated glaucoma laser therapy. The company has raised about $45 million to date, including grants from the European Union and the Israel Innovation Authority. All Belkin shares will be transferred to a wholly-owned subsidiary of Alcon, with BioLight to receive $9 million in cash immediately upon completion of the transaction, and an additional future compensation of up to $10.8 million, depending on meeting milestones.
Acquisition
Team Members
1
Employees: 11-50
Web & Social Links
| Website | www.alcon.com/ |
Locations
Yavne, Israel
Fort Worth, TX, USA
Photos & Videos
No files yet
Alcon Pharmaceuticals Business
Business models
—
Product stage
—
Employees
11-50
Sector
—Target Customer
—Core Technology
—Tags (1)
medical-devicesAlcon Pharmaceuticals Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Alcon Pharmaceuticals Lifecycle
Alcon Pharmaceuticals News
2 articles
growth-positive
CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls
The article highlights recent research calls on Wall Street, focusing on upgrades and downgrades of various companies. HP Enterprise (HPE) was upgraded by Morgan Stanley to Overweight with a price target increase, indicating a positive outlook due to potential benefits from the Juniper acquisition. CoreWeave and Bio-Techne also received upgrades with increased price targets, suggesting undervaluation and growth potential. Conversely, companies like Instacart and Coty faced downgrades due to increased competition and weaker-than-expected results. The article provides insights into market perceptions and expectations for these companies.
growth-positive
Alcon acquiring glaucoma laser therapy developer Belkin Vision for up to $330 million | CTech
Alcon Pharmaceuticals is acquiring Israeli healthtech company Belkin Vision, according to a report filed by BioLight to the Tel Aviv Stock Exchange. Belkin Vision, valued at up to $330 million, has developed a non-contact automated glaucoma laser therapy. The company has raised about $45 million to date, including grants from the European Union and the Israel Innovation Authority. All Belkin shares will be transferred to a wholly-owned subsidiary of Alcon, with BioLight to receive $9 million in cash immediately upon completion of the transaction, and an additional future compensation of up to $10.8 million, depending on meeting milestones.
Acquisition
Alcon Pharmaceuticals Team
Daria Lemann-Blumenthal
Employee Info
| Employees (range) | 11-50 |
| Exact count | 25 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Alcon Pharmaceuticals Internal
Recent Updates
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:42:49.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:24:09.000000
Jenny Sotnik-Talisman
· jenny.sotnik@sncentral.org · Manual · 2025-04-23 11:32:40.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:24:10.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:24:09.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:30:22.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:44:02.000000
Jenny Sotnik-Talisman
· jenny.sotnik@sncentral.org · Automatic · 2025-04-23 11:32:41.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:24:15.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:24:09.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:30:21.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2024-05-05 11:47:54.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:24:09.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:15:53.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-22 06:27:04.000000
Matan Eblagon
· matane@sncentral.org · Automatic · 2024-05-05 11:47:54.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:24:09.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:30:22.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:30:19.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:25:00.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:24:09.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:43:30.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:30:19.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:25:51.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2025-02-06 12:43:50.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:30:21.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2024-07-16 08:25:00.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:30:19.000000
Maor Perlov
· maor.perlov@sncentral.org · Automatic · 2024-07-16 08:30:21.000000
Matan Eblagon
· matane@sncentral.org · Automatic · 2024-05-05 11:47:54.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 53/100 |
| Missing | product stage, sector, tags, business model, description, video or image, funding rounds, markets, not claimed |
| BI Verification | Maor Perlov |
| Crunchbase | alcon |
| Creator | Matan Eblagon |
| Creator email | matane@sncentral.org |
| Last update | 2024-05-05T00:00:00.000Z |
| Created | 2024-05-05T00:00:00.000Z |
| Status detail | Public on SIX on Apr, 2019;Public on NYSE on Apr, 2019; |